Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

NEW YORK – Immuneering on Thursday said it signed a clinical supply agreement with Regeneron to obtain the anti-PD-1 therapy Libtayo (cemiplimab) for a Phase IIa trial testing Immuneering's MEK ...

Moncyte Health's test evaluates biological differences in how cholesterol is transported and processed in cells, which can ...

Within the open-label basket trial, patients with two copies of one of two high-risk APOL1 gene variants will receive MZE829.

Pfizer's oncology business reported strong growth in Q4 as the firm looks ahead to further expansion of its breast cancer and ...

The FDA, which has stopped short of requiring DPYD testing for patients before receiving fluoropyrimidines, emphasized the ...

These boards are cropping up around the US as neurologists acclimate to a new class of drugs, but not everyone agrees such ...

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

NEW YORK – Currently available large language models (LLMs) are not accurate enough to use safely for clinical decision support, but physician-scientists are continuing to test artificial intelligence ...

The positive results from the second part of the EMBARK trial contrast with findings from one-year post treatment, which did ...